{
    "clinical_study": {
        "@rank": "82242", 
        "arm_group": [
            {
                "arm_group_label": "PF-02545920", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally\n      to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/-\n      other adjunctive medication."
        }, 
        "brief_title": "A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Psychiatrically stable subjects with schizophrenia.\n\n          -  Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.\n\n          -  Subjects must be on a stable medication treatment regimen greater than or equal to 2\n             months, including concomitant psychotropic medications.\n\n        Exclusion Criteria:\n\n          -  History of seizures or of a condition with risk of seizures.\n\n          -  Subjects who have had electroconvulsive therapy within the 6 months prior to\n             randomization.\n\n          -  Pregnant or nursing females, and females of child bearing potential."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829048", 
            "org_study_id": "A8241018"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-02545920", 
                "description": "15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h", 
                "intervention_name": "PF-02545920", 
                "intervention_type": "Drug", 
                "other_name": "Cohort 1"
            }, 
            {
                "arm_group_label": "PF-02545920", 
                "description": "15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h", 
                "intervention_name": "PF-02545920", 
                "intervention_type": "Drug", 
                "other_name": "Cohort 2"
            }, 
            {
                "arm_group_label": "PF-02545920", 
                "description": "15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h", 
                "intervention_name": "PF-02545920", 
                "intervention_type": "Drug", 
                "other_name": "Cohort 3"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo Q12h", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-02545920", 
            "safety", 
            "schizophrenia"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241018&StudyName=A%20Study%20To%20Examine%20The%20Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Of%20PF-02545920%20In%20Psychiatrically%20Stable%20Subjects%20With%20Schizophrenia%20%20%"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A)", 
                "safety_issue": "Yes", 
                "time_frame": "Cohorts 1 and 2: Screening, Day 0, Days 1-6, Day 8, Day/Early Termination Visit / Cohort 3: Screening, Day 0, Days 1-3, Days 8-10, Days 15-17, Day 18/Early Termination Visit"
            }, 
            {
                "measure": "Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Cohorts 1 and 2: Screening, Day 0, Day 10/Early Termination Visit, Day 11, Follow-up / Cohort 3: Screening, Day 0, Day 18/Early Termination Visit, Day 19, Follow-up"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829048"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}